

Claims:

1. Use of active dendritic cells (DCs) releasing interleukin 12 (IL-12) which are loaded with an antigen against a specific pathogen or a specific tumor and, due to the treatment with lipopolysaccharide (LPS) and interferon-gamma (IFN- γ), release IL-12, for the preparation of a medicament for treating a patient having an infection with said specific pathogen or for treating a patient having said specific tumor.
2. Use according to claim 1, characterised in that said treatment is performed after bone marrow transplantation.
3. Use according to claim 1 or 2, characterised in that said specific tumor is an advanced malignancy.
4. Use according to any one of claims 1 to 3, characterised in that said DCs are DCs having been taken from the patient having an infection with said specific pathogen or from the patient having said specific tumor or from the bone marrow donor.
5. Use according to any one of claims 1 to 4, characterised in that the DCs have been loaded with an antigen from a tumor cell from said patient having said specific tumor.
6. Use according to any one of claims 1 to 5, characterised in that the DCs are additionally charged with a tracer antigen.
7. Use according to claim 6, characterised in that said tracer antigen is keyhole limpet hemocyanine (KLH).
8. Use according to any one of claims 1 to 7, characterised in that the DCs are additionally charged with an adjuvant, especially with tetanus toxoid.
9. Use according to any one of claims 1 to 8, characterised in that the DCs have been generated in vitro from peripheral blood mononuclear cells (PBMCs).